- About us
- About Vaccines
- Media centre
- EU initiatives
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Breakthroughs only come about because of the passion, commitment and dedication of individuals, teams and companies working to discover and develop new vaccines for patients.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
UTRECHT and BILTHOVEN, Netherlands, Feb. 4, 2019 /PRNewswire/ — Recently, the EU-sponsored Vaccines andInfecTious diseases in the Ageing popuLation (VITAL) project was launched. VITAL will address – in a public-private consortium – the challenges of infections in the elderly and the potential of infection prevention by vaccination.
Within the VITAL project, which will run from 2019-2023, University Medical Center (UMC) Utrecht will be the managing entity and scientific lead. The € 12.4 million project is sponsored by the European Union’s Innovative Medicines Initiative(IMI) with a grant of € 5.5 million which will be matched by grants in total of € 6.9 million from the European Federation of Pharmaceutical Industries Associations (EFPIA). The consortium academic leader is prof. dr. Debbie van Baarle, professor of Immunology of Vaccinations at UMC Utrecht and Head of the Department of Immune Mechanisms at the Centre for Immunology of Infectious Diseases and Vaccines at the National Institute of Health and the Environment(RIVM) in the Netherlands.
See the full press release here.
7th December 2018
Vaccines Europe welcomes the EU Council Recommendation on strengthened cooperation against vaccine-preventable diseases. Speaking about the Recommendation, Pascale Mauran, President of Vaccines Europe said “The Recommendation represents a major step towards addressing the different vaccines and vaccination-related challenges faced by the EU Member States such as increasing vaccination hesitancy, low vaccine uptake. Implementing the Recommendation will require stronger collaboration between all relevant stakeholders, in particular, national public health authorities and the European Commission. At Vaccines Europe we are looking forward to collaborating and supporting the implementation of the EU Council Recommendation in order to secure full protection of all EU citizens against vaccine-preventable diseases.”
Vaccination is one of the most powerful and cost-effective public health measures developed in the 20th century and remains the main tool for primary prevention of communicable diseases. Vaccination programs should go beyond childhood, taking a life-course approach to address epidemiological shifts in the burden of vaccine-preventable diseases. Moreover, vaccination can be an important instrument in addressing antimicrobial resistance.
Read the full Vaccines Europe statement here.
The six undersigned European health industry associations are ambitious about a healthier future for the European citizens, based on medical innovation, timely access to quality health interventions, better health outcomes for patients, and affordable healthcare. Horizon Europe has a key role to play in that future.
Vaccines Europe recognises the enormous and decade-long commitment of the European Centre for Disease Prevention and Control and the European Commission to raising awareness about the global problem of antimicrobial resistance (AMR), in the European population. This major public health threat has made the EU and other countries worldwide take certain steps in order to protect their citizens from dangerous bacteria. Read our full statement here.